GCL
EBACU

Glazer Capital LLC’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Glazer Capital LLC’s Portfolio EBACU Stock Details EBACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-239,510
Closed -$2.37M – 806
2021
Q4 		$2.37M Sell
239,510
-29,465
-11% -$292K 0.06% 308
2021
Q3 		$2.66M Sell
268,975
-15,129
-5% -$150K 0.05% 361
2021
Q2 		$2.84M Sell
284,104
-25,896
-8% -$259K 0.04% 385
2021
Q1 		$3.12M Buy
+310,000
New +$3.1M 0.04% 406

Other funds holding EBACU

MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.61% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Glazer Capital LLC's EBACU Position: Q1 2022 in Review

Glazer Capital LLC sold out of European Biotech Acquisition Corp. Units (EBACU) in Q1 2022, closing a stake of 239,510 shares — an estimated $2.37M sold.

Glazer Capital LLC first reported a position in EBACU in Q1 2021 and held it in 4 quarters. The position peaked at $3.12M in Q1 2021. 22 funds tracked by Wall St. Rank hold EBACU as of Q1 2022.

  • Glazer Capital LLC reported no remaining European Biotech Acquisition Corp. Units position as of Q1 2022 after selling out during the quarter.
  • Glazer Capital LLC sold 239,510 European Biotech Acquisition Corp. Units shares in Q1 2022, an estimated $2.37M.
  • Glazer Capital LLC first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 4 quarters.
  • Glazer Capital LLC's European Biotech Acquisition Corp. Units position peaked at $3.12M in Q1 2021.
  • 22 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q1 2022.

Based on Glazer Capital LLC's 13F filing for Q1 2022, filed 17 May 2022.